BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Catela Ivkovic T, Voss G, Cornella H, Ceder Y. microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Letters 2017;407:113-22. [DOI: 10.1016/j.canlet.2017.04.007] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Deng G, Qi Y, Zhang H, Jiang H, Geng R, Ye Z, Liu B, Chen Q. Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma. Biomed Res Int 2020;2020:9716720. [PMID: 32695826 DOI: 10.1155/2020/9716720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mohammadi-Yeganeh S, Hosseini V, Paryan M. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. J Cell Physiol 2019;234:18317-28. [PMID: 30945294 DOI: 10.1002/jcp.28465] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
3 Zhu D, Yang C, Shen P, Chen L, Chen J, Sun X, Duan L, Zhang L, Zhu J, Duan Y. rSjP40 suppresses hepatic stellate cell activation by promoting microRNA-155 expression and inhibiting STAT5 and FOXO3a expression. J Cell Mol Med 2018;22:5486-93. [PMID: 30091834 DOI: 10.1111/jcmm.13819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Zhu B, Chen W, Fu Y, Cui X, Jin L, Chao J, Yun X, Gao P, Shan S, Li J, Yin X, Zhu C, Qin X. MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells. Onco Targets Ther 2020;13:6873-84. [PMID: 32764979 DOI: 10.2147/OTT.S256153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Plantamura I, Cosentino G, Cataldo A. MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. Front Oncol 2018;8:352. [PMID: 30234015 DOI: 10.3389/fonc.2018.00352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M. miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Mol Ther Nucleic Acids 2018;11:485-93. [PMID: 29858083 DOI: 10.1016/j.omtn.2018.04.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
7 Ji C, Guo X. The clinical potential of circulating microRNAs in obesity. Nat Rev Endocrinol 2019;15:731-43. [PMID: 31611648 DOI: 10.1038/s41574-019-0260-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 24.5] [Reference Citation Analysis]
8 Khomtchouk BB, Tran DT, Vand KA, Might M, Gozani O, Assimes TL. Cardioinformatics: the nexus of bioinformatics and precision cardiology. Brief Bioinform 2020;21:2031-51. [PMID: 31802103 DOI: 10.1093/bib/bbz119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Du X, Tian D, Wei J, Yan C, Hu P, Wu X, Yang W, Zhu Z. miR-199a-5p Exacerbated Intestinal Barrier Dysfunction through Inhibiting Surfactant Protein D and Activating NF-κB Pathway in Sepsis. Mediators Inflamm 2020;2020:8275026. [PMID: 32508527 DOI: 10.1155/2020/8275026] [Reference Citation Analysis]
10 Xu H, Wang X, Zhang Y, Zheng W, Zhang H. GATA6-AS1 inhibits ovarian cancer cell proliferation and migratory and invasive abilities by sponging miR-19a-5p and upregulating TET2. Oncol Lett 2021;22:718. [PMID: 34429758 DOI: 10.3892/ol.2021.12979] [Reference Citation Analysis]
11 Qin RF, Zhang J, Huo HR, Yuan ZJ, Xue JD. MiR-205 mediated APC regulation contributes to pancreatic cancer cell proliferation. World J Gastroenterol 2019; 25(28): 3775-3786 [PMID: 31391772 DOI: 10.3748/wjg.v25.i28.3775] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
12 Fudalej MM, Badowska-Kozakiewicz AM. Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes. Oncol Lett 2021;21:417. [PMID: 33841578 DOI: 10.3892/ol.2021.12678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang Q, Wang G, Xu X, Chen Z. miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2. Pathol Res Pract 2021;222:153420. [PMID: 33887625 DOI: 10.1016/j.prp.2021.153420] [Reference Citation Analysis]
14 Lyu H, Huang J, He Z, Liu B. Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells. Biol Proced Online 2018;20:16. [PMID: 30093840 DOI: 10.1186/s12575-018-0081-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Shams R, Asadzadeh Aghdaei H, Behmanesh A, Sadeghi A, Zali M, Salari S, Padrón JM. MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review. Cancer Manag Res 2020;12:2393-404. [PMID: 32308478 DOI: 10.2147/CMAR.S245872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 He Z, Dang J, Song A, Cui X, Ma Z, Zhang Y. The involvement of miR-150/β-catenin axis in colorectal cancer progression. Biomedicine & Pharmacotherapy 2020;121:109495. [DOI: 10.1016/j.biopha.2019.109495] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Che X, Qian Y, Li D. Suppression of Disheveled–Axin Domain Containing 1 (DIXDC1) by MicroRNA-186 Inhibits the Proliferation and Invasion of Retinoblastoma Cells. J Mol Neurosci 2018;64:252-61. [DOI: 10.1007/s12031-017-1017-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sun W, Yi Y, Xia G, Zhao Y, Yu Y, Li L, Hua C, He B, Yang B, Yu C, Ye C, Tu F, Chen C, Xu X, Zheng Z, Wang W, Shen X. Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy. Mol Ther 2019;27:1039-50. [PMID: 30852137 DOI: 10.1016/j.ymthe.2019.02.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
19 Kumar S, Sarthi P, Mani I, Ashraf MU, Kang MH, Kumar V, Bae YS. Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells 2021;10:2250. [PMID: 34571899 DOI: 10.3390/cells10092250] [Reference Citation Analysis]
20 Lyu H, Wang S, Huang J, Wang B, He Z, Liu B. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 2018;420:97-108. [PMID: 29409974 DOI: 10.1016/j.canlet.2018.01.065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
21 Fan X, Jin S, Li Y, Khadaroo PA, Dai Y, He L, Zhou D, Lin H. Genetic And Epigenetic Regulation Of E-Cadherin Signaling In Human Hepatocellular Carcinoma. Cancer Manag Res 2019;11:8947-63. [PMID: 31802937 DOI: 10.2147/CMAR.S225606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
22 Zhang J, He J, Zhang L. The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling. Biomed Pharmacother 2018;106:35-42. [PMID: 29945115 DOI: 10.1016/j.biopha.2018.06.099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
23 Voss G, Haflidadóttir BS, Järemo H, Persson M, Catela Ivkovic T, Wikström P, Ceder Y. Regulation of cell-cell adhesion in prostate cancer cells by microRNA-96 through upregulation of E-Cadherin and EpCAM. Carcinogenesis 2020;41:865-74. [PMID: 31738404 DOI: 10.1093/carcin/bgz191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Liu X, Shao Y, Zhou J, Qian G, Ma Z. Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy. Mol Ther Nucleic Acids 2020;19:208-17. [PMID: 31841993 DOI: 10.1016/j.omtn.2019.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
25 Eringyte I, Zamarbide Losada JN, Powell SM, Bevan CL, Fletcher CE. Coordinated AR and microRNA regulation in prostate cancer. Asian J Urol 2020;7:233-50. [PMID: 32742925 DOI: 10.1016/j.ajur.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Della Rosa G, Di Corato R, Carpi S, Polini B, Taurino A, Tedeschi L, Nieri P, Rinaldi R, Aloisi A. Tailoring of silica-based nanoporous pod by spermidine multi-activity. Sci Rep 2020;10:21142. [PMID: 33273530 DOI: 10.1038/s41598-020-77957-4] [Reference Citation Analysis]
27 Nie D, Fu J, Chen H, Cheng J, Fu J. Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential. Int J Mol Sci 2019;20:E861. [PMID: 30781524 DOI: 10.3390/ijms20040861] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
28 Basnet U, Patil AR, Kulkarni A, Roy S. Role of Stress-Survival Pathways and Transcriptomic Alterations in Progression of Colorectal Cancer: A Health Disparities Perspective. Int J Environ Res Public Health 2021;18:5525. [PMID: 34063993 DOI: 10.3390/ijerph18115525] [Reference Citation Analysis]
29 Zhao Z, Lin CY, Cheng K. siRNA- and miRNA-based therapeutics for liver fibrosis. Transl Res 2019;214:17-29. [PMID: 31476281 DOI: 10.1016/j.trsl.2019.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
30 Ding L, Lan Z, Xiong X, Ao H, Feng Y, Gu H, Yu M, Cui Q. The Dual Role of MicroRNAs in Colorectal Cancer Progression. Int J Mol Sci. 2018;19. [PMID: 30227605 DOI: 10.3390/ijms19092791] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
31 Santangelo A, Tamanini A, Cabrini G, Dechecchi MC. Circulating microRNAs as emerging non-invasive biomarkers for gliomas. Ann Transl Med 2017;5:277. [PMID: 28758103 DOI: 10.21037/atm.2017.06.15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
32 Fu Q, Gao Y, Yang F, Mao T, Sun Z, Wang H, Song B, Li X. Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/β-catenin signaling. Biomed Pharmacother 2018;97:120-7. [PMID: 29080452 DOI: 10.1016/j.biopha.2017.10.115] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
33 Ji C, Xu Q, Guo L, Wang X, Ren Y, Zhang H, Zhu W, Ming Z, Yuan Y, Ren X, Song J, Cheng Y, Yang J, Zhang Y. eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells. Cancer Letters 2018;418:64-74. [DOI: 10.1016/j.canlet.2018.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Petrovic N, Ergun S. miRNAs as Potential Treatment Targets and Treatment Options in Cancer. Mol Diagn Ther 2018;22:157-68. [DOI: 10.1007/s40291-017-0314-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
35 Li DF, Yuan Y, Tu MJ, Hu X, Li YZ, Yi WR, Li PC, Zhao Y, Cheng Z, Yu AM, Jian C, Yu AX. The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug. Front Oncol 2020;10:222. [PMID: 32161722 DOI: 10.3389/fonc.2020.00222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S, He L, Shan A, Zhang Y, Yu X. Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. Int J Nanomedicine. 2018;13:1241-1256. [PMID: 29535520 DOI: 10.2147/ijn.s158290] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
37 Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev 2018;37:33-44. [PMID: 29282605 DOI: 10.1007/s10555-017-9724-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 31.5] [Reference Citation Analysis]
38 Yang Z, Sun Q, Guo J, Wang S, Song G, Liu W, Liu M, Tang H. GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy 2019;15:668-85. [PMID: 30394198 DOI: 10.1080/15548627.2018.1539590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
39 Biber G, Ben-Shmuel A, Sabag B, Barda-Saad M. Actin regulators in cancer progression and metastases: From structure and function to cytoskeletal dynamics. Int Rev Cell Mol Biol 2020;356:131-96. [PMID: 33066873 DOI: 10.1016/bs.ircmb.2020.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biol Proced Online 2019;21:5. [PMID: 30930695 DOI: 10.1186/s12575-019-0093-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
41 Wang W, Liu B, Sun S, Lan L, Chen Y, Han S, Li X, Li Z. Downregulation of miR-486-5p Enhances the Anti-Tumor Effect of 5-Fluorouracil on Pancreatic Cancer Cells. Onco Targets Ther 2020;13:1649-59. [PMID: 32158231 DOI: 10.2147/OTT.S231153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 El-Khazragy N, Noshi MA, Abdel-Malak C, Zahran RF, Swellam M. miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. J Cell Biochem. 2019;120:6315-6321. [PMID: 30362157 DOI: 10.1002/jcb.27918] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
43 Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, Xie H, Zhou L, Zheng S. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett 2018;15:9126-32. [PMID: 29805644 DOI: 10.3892/ol.2018.8539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Sun Y, Wang R, Qiao M, Xu Y, Guan W, Wang L. Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. J Cell Physiol 2018;233:6359-69. [PMID: 29334123 DOI: 10.1002/jcp.26433] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
45 Liu J, Cao L, Zhao N, Feng Y, Yu Z, Li Y, Teng C, Hu J, Li T. miR‑338‑3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and β‑catenin signaling pathways. Mol Med Rep 2019;20:33-40. [PMID: 31115502 DOI: 10.3892/mmr.2019.10215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
46 Li J, Rodriguez G, Han X, Janečková E, Kahng S, Song B, Chai Y. Regulatory Mechanisms of Soft Palate Development and Malformations. J Dent Res 2019;98:959-67. [PMID: 31150594 DOI: 10.1177/0022034519851786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
47 Chen H, Xu Z, Liu D. Small non-coding RNA and colorectal cancer. J Cell Mol Med 2019;23:3050-7. [PMID: 30801950 DOI: 10.1111/jcmm.14209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
48 Shukla GC, Gupta S. Hallmarks of cancer- focus on RNA metabolism and regulatory noncoding RNAs. Cancer Lett 2018;420:208-9. [PMID: 29409790 DOI: 10.1016/j.canlet.2018.01.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Urooj T, Wasim B, Mushtaq S, Shah SNN, Shah M. Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects. Curr Cancer Drug Targets 2020;20:168-86. [PMID: 31858911 DOI: 10.2174/1568009620666191220151856] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
50 Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X. Overexpression of TONSL might be an independent unfavorable prognostic indicator in hepatocellular carcinoma. Pathol Res Pract 2019;215:939-45. [PMID: 30723051 DOI: 10.1016/j.prp.2019.01.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
51 Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer 2017;117:409-20. [PMID: 28641312 DOI: 10.1038/bjc.2017.191] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
52 Chen C, Tian A, Zhou H, Zhang X, Liu Z, Ma X. Upregulation of miR-211 Promotes Chondrosarcoma Development via Targeting Tumor Suppressor VHL. Onco Targets Ther 2020;13:2935-43. [PMID: 32308426 DOI: 10.2147/OTT.S239887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Boscaino V, Fiannaca A, La Paglia L, La Rosa M, Rizzo R, Urso A. MiRNA therapeutics based on logic circuits of biological pathways. BMC Bioinformatics 2019;20:344. [PMID: 31757209 DOI: 10.1186/s12859-019-2881-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Xu S, Hazlett LD. MicroRNAs in Ocular Infection. Microorganisms 2019;7:E359. [PMID: 31533211 DOI: 10.3390/microorganisms7090359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Qiu Y, Shan W, Yang Y, Jin M, Dai Y, Yang H, Jiao R, Xia Y, Liu Q, Ju L, Huang G, Zhang J, Yang L, Li L, Li Y. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α. Cell Death Discov 2019;5:120. [PMID: 31341646 DOI: 10.1038/s41420-019-0200-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
56 Chen J, Tang Y, Liu Y, Dou Y. Nucleic Acid-Based Therapeutics for Pulmonary Diseases. AAPS PharmSciTech 2018;19:3670-80. [PMID: 30338490 DOI: 10.1208/s12249-018-1183-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
57 Nayak R, Meerovich I, Dash AK. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment. AAPS PharmSciTech 2019;20. [DOI: 10.1208/s12249-019-1367-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
58 Catuogno S, Esposito CL, Condorelli G, de Franciscis V. Nucleic acids delivering nucleic acids. Adv Drug Deliv Rev 2018;134:79-93. [PMID: 29630917 DOI: 10.1016/j.addr.2018.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
59 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Jiang M, Lu W, Ding X, Liu X, Guo Z, Wu X. p16INK4a inhibits the proliferation of osteosarcoma cells through regulating the miR-146b-5p/TRAF6 pathway. Biosci Rep 2019;39:BSR20181268. [PMID: 30643010 DOI: 10.1042/BSR20181268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
61 Huang Y, Huang H, Li M, Zhang X, Liu Y, Wang Y. MicroRNA-374c-5p regulates the invasion and migration of cervical cancer by acting on the Foxc1/snail pathway. Biomed Pharmacother 2017;94:1038-47. [PMID: 28810526 DOI: 10.1016/j.biopha.2017.07.150] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
62 Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2878-92. [DOI: 10.1007/s10620-019-05608-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
63 Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 2018;39:1073-84. [PMID: 29877320 DOI: 10.1038/aps.2018.30] [Cited by in Crossref: 156] [Cited by in F6Publishing: 137] [Article Influence: 52.0] [Reference Citation Analysis]
64 Von den Hoff JW, Carvajal Monroy PL, Ongkosuwito EM, van Kuppevelt TH, Daamen WF. Muscle fibrosis in the soft palate: Delivery of cells, growth factors and anti-fibrotics. Adv Drug Deliv Rev 2019;146:60-76. [PMID: 30107211 DOI: 10.1016/j.addr.2018.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]